About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
F2rtm1Pago
targeted mutation 1, Patricia Andrade-Gordon
MGI:3038377
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
F2rtm1Pago/F2rtm1Pago B6.129P2-F2rtm1Pago MGI:3826826
hm2
F2rtm1Pago/F2rtm1Pago involves: 129P2/OlaHsd MGI:4822460
hm3
F2rtm1Pago/F2rtm1Pago involves: 129P2/OlaHsd * C57BL/6 MGI:3038598
cx4
F2rtm1Pago/F2rtm1Pago
F3tm1.1Dwr/F3tm1.1Dwr
B6.129-F3tm1.1Dwr F2rtm1Pago MGI:4829887
cx5
F2rtm1Pago/F2rtm1Pago
Tg(MMTV-PyVT)634Mul/0
B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul MGI:4821159


Genotype
MGI:3826826
hm1
Allelic
Composition
F2rtm1Pago/F2rtm1Pago
Genetic
Background
B6.129P2-F2rtm1Pago
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
F2rtm1Pago mutation (0 available); any F2r mutation (23 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
N
• retinal neoangiogenesis after oxygen induced retinopathy is similar to wild-type mice
• although the size of cardiac infarctions is unaffected, the extent of left ventricular dilation after infarction and recovery is reduced
• less impairment of left ventricular function after cardiac infarction and recovery

homeostasis/metabolism
• less impairment of left ventricular function after cardiac infarction and recovery

immune system
N
• mice show no differences in high dose (100% lethal challenge) lipopolysaccharide (LPS)-induced inflammation and lethality compared to controls




Genotype
MGI:4822460
hm2
Allelic
Composition
F2rtm1Pago/F2rtm1Pago
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
F2rtm1Pago mutation (0 available); any F2r mutation (23 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mutants exhibit increased survival over wild-type mice after 90%, but not 100%, lethal LPS challenge

homeostasis/metabolism
• decrease in IL-6 and IL-1beta levels six hours after 90% lethal LPS challenge
• increase in IL-1beta levels in mesenteric lymph nodes but reduced levels in the lungs after LPS challenge

immune system
• decrease in IL-6 and IL-1beta levels six hours after 90% lethal LPS challenge
• increase in IL-1beta levels in mesenteric lymph nodes but reduced levels in the lungs after LPS challenge
• 18 hours after LPS challenge, lymph nodes exhibit abundant fibrin throughout the parenchyma compared to staining within lymphatic ducts in wild-type
• mesenteric lymph nodes are 3 times larger than in wild-type 18 hours after LPS challenge
• mutants exhibit a similar level of initial development of inflammation as wild-type mice in response to severe challenge with lipopolysaccharide (LPS), however attenuation of the inflammation occurs 12-18 hours after challenge while wild-type mice succumb to the infection




Genotype
MGI:3038598
hm3
Allelic
Composition
F2rtm1Pago/F2rtm1Pago
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
F2rtm1Pago mutation (0 available); any F2r mutation (23 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• a large portion of embryos are resorbed after E10, though some mice develop normally and survive to adulthood

cardiovascular system
N
• mice that survive to adulthood exhibit normal platelet number and function, coagulation parameters, basal heart rate, and arterial blood pressure (J:38032)
• mutants exhibit normal pulmonary vasoreactivity to vasoactive mediators (J:124465)
• cell density is greater in normal carotids from mutants than in wild-type mice
• mutants exhibit a reduction of the hypertensive response to the selective thrombin receptor activating peptide, SFLLRN-NH2, before and after L-NAME (an inhibitor of nitric oxide synthesis) and absence of hypertension in the presence of L-NAME
• mutants show absence of an arterial pressure response to the selective thrombin receptor activating peptide, TFLLRNPNDK-NH2
• the hypertensive response and heart rate decrease in response to TFLLRNPNDK, a F2r (PAR-1) selective activating peptide, is absent
• SFLLRN, a nonselective receptor activating peptide, was able to induce hypotension in mutants as in wild-type mice but the heart rate decrease and secondary hypotension following L-NAME are absent
• the thrombin-induced increase in pulmonary microvessel permeability seen in controls is absent in mutants
• vessel diameter is unchanged and lumen diameter decreases following vascular injury unlike in wild-type mice in which vessel and lumen diameters increase following injury
• area of neointima formation following vascular injury is slightly less than in wild-type mice
• however, medial cell loss, incidence of thrombosis, endothelial regrowth, and medial thickening after injury are similar to wild-type

reproductive system
• matings between homozygous mice occur infrequently and produce less than 3 offspring

homeostasis/metabolism
• vessel diameter is unchanged and lumen diameter decreases following vascular injury unlike in wild-type mice in which vessel and lumen diameters increase following injury
• area of neointima formation following vascular injury is slightly less than in wild-type mice
• however, medial cell loss, incidence of thrombosis, endothelial regrowth, and medial thickening after injury are similar to wild-type

digestive/alimentary system
• mutants have a lower baseline short-circuit current in the colon than wild-type mice but no difference in the short-circuit current response to electrical field stimulation, indicating abnormal basal ion secretion in the colon
• trinitrobenzene sulfonic acid (TNBS) induced colitis is less severe in mutants than in wild-type mice

immune system
• absence of human trypsin IV and rat p23 induced edema and granulocyte infiltration after intraplantar injection
• trinitrobenzene sulfonic acid (TNBS) induced colitis is less severe in mutants than in wild-type mice




Genotype
MGI:4829887
cx4
Allelic
Composition
F2rtm1Pago/F2rtm1Pago
F3tm1.1Dwr/F3tm1.1Dwr
Genetic
Background
B6.129-F3tm1.1Dwr F2rtm1Pago
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
F2rtm1Pago mutation (0 available); any F2r mutation (23 available)
F3tm1.1Dwr mutation (0 available); any F3 mutation (24 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• mice exhibit enhanced retinal revascularization following oxygen induced retinopathy; the superficial vascular plexus reforms more quickly than in wild-type mice

vision/eye
• mice exhibit enhanced retinal revascularization following oxygen induced retinopathy; the superficial vascular plexus reforms more quickly than in wild-type mice




Genotype
MGI:4821159
cx5
Allelic
Composition
F2rtm1Pago/F2rtm1Pago
Tg(MMTV-PyVT)634Mul/0
Genetic
Background
B6.Cg-F2rtm1Pago Tg(MMTV-PyVT)634Mul
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
F2rtm1Pago mutation (0 available); any F2r mutation (23 available)
Tg(MMTV-PyVT)634Mul mutation (2 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• progression of mammary adenocarcinoma development occurs to a similar extent as in Tg(MMTV-PyVT)634Mul mice
• adenomas develop by 9 weeks of age, at similar time and rate as in Tg(MMTV-PyVT)634Mul mice

integument
• progression of mammary adenocarcinoma development occurs to a similar extent as in Tg(MMTV-PyVT)634Mul mice

endocrine/exocrine glands
• progression of mammary adenocarcinoma development occurs to a similar extent as in Tg(MMTV-PyVT)634Mul mice





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/16/2024
MGI 6.23
The Jackson Laboratory